Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3877039> ?p ?o }
Showing triples 1 to 47 of
47
with 100 triples per page.
- Q3877039 subject Q6809004.
- Q3877039 abstract "Nimotuzumab (h-R3, BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials. Like cetuximab, nimotuzumab binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a chimeric human-mouse h-R3 heavy chain and a human-mouse h-R3 κ-chain.".
- Q3877039 atcPrefix "L01XC".
- Q3877039 casNumber "780758-10-3, 828933-51-3".
- Q3877039 wikiPageExternalLink www.eurofarma.com.br.
- Q3877039 wikiPageWikiLink Q127076.
- Q3877039 wikiPageWikiLink Q1365309.
- Q3877039 wikiPageWikiLink Q148.
- Q3877039 wikiPageWikiLink Q14865565.
- Q3877039 wikiPageWikiLink Q155.
- Q3877039 wikiPageWikiLink Q1563.
- Q3877039 wikiPageWikiLink Q1693598.
- Q3877039 wikiPageWikiLink Q1783924.
- Q3877039 wikiPageWikiLink Q180507.
- Q3877039 wikiPageWikiLink Q186889.
- Q3877039 wikiPageWikiLink Q212961.
- Q3877039 wikiPageWikiLink Q241.
- Q3877039 wikiPageWikiLink Q275419.
- Q3877039 wikiPageWikiLink Q3658562.
- Q3877039 wikiPageWikiLink Q3776943.
- Q3877039 wikiPageWikiLink Q38933.
- Q3877039 wikiPageWikiLink Q414.
- Q3877039 wikiPageWikiLink Q41861.
- Q3877039 wikiPageWikiLink Q419.
- Q3877039 wikiPageWikiLink Q420296.
- Q3877039 wikiPageWikiLink Q422248.
- Q3877039 wikiPageWikiLink Q425158.
- Q3877039 wikiPageWikiLink Q5059992.
- Q3877039 wikiPageWikiLink Q633403.
- Q3877039 wikiPageWikiLink Q668.
- Q3877039 wikiPageWikiLink Q669441.
- Q3877039 wikiPageWikiLink Q6809004.
- Q3877039 wikiPageWikiLink Q681817.
- Q3877039 wikiPageWikiLink Q739.
- Q3877039 wikiPageWikiLink Q843.
- Q3877039 wikiPageWikiLink Q949267.
- Q3877039 wikiPageWikiLink Q96.
- Q3877039 wikiPageWikiLink Q974135.
- Q3877039 atcPrefix "L01XC".
- Q3877039 casNumber "780758".
- Q3877039 type ChemicalSubstance.
- Q3877039 type Drug.
- Q3877039 type ChemicalObject.
- Q3877039 type Thing.
- Q3877039 type Q8386.
- Q3877039 comment "Nimotuzumab (h-R3, BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.".
- Q3877039 label "Nimotuzumab".